WADA Signs Historic Agreement with Pharma Giant GlaxoSmithKline

Guardar

Montreal, July 4, 2011 – The World Anti-Doping Agency (WADA) has signed a long-term agreement with GlaxoSmithKline (GSK) that will help the agency create early detection methods for medicines that have performance-enhancing potential in sport.

The historic partnership, which was officially ratified in London on June 21, will see GSK supply WADA with confidential information about medicines in early stage development that could be abused by athletes once they are licensed for appropriate patient use.

It covers all new medicines being developed by GSK and builds on the company’s role as the Official Laboratory Services provider for the 2012 Olympic and Paralympic Games.

Currently, WADA mostly has access to scientific information relating to medicines which have been licensed. Although all medicines have been researched and produced to deliver health benefits for patients, there have been examples of illegitimate use by a minority of athletes seeking advantage in sport.

Under the new agreement, medicines in development will be reviewed by GSK scientists specifically to identify substances with a probable or high risk of abuse in sport.

These scientists will look for any similarity to the pharmacological characteristics of existing performance-enhancing substances and assess how they work in the human body. This would include stimulatory effects or improved physical endurance.

Any substances found to have performance-enhancing characteristics will be highlighted to WADA and confidential scientific data relating to them will be transferred by GSK so they can begin work on detection methods.

John Fahey, WADA President, said: "Our work with the pharmaceutical industry is critical to staying one step ahead of the dopers, who have an ever increasing level of scientific expertise. We are delighted to be entering into this partnership with GSK as it will play a significant role in helping WADA achieve its mission of a doping free sporting culture."

Patrick Vallance, SVP Medicines Discovery and Development said: "The safe and effective use of our medicines, in appropriate patients, is our top priority. Unfortunately there is always potential for illegitimate abuse by athletes. We hope that our contribution of laboratory services to the London 2012 Games and this longer term partnership with WADA will demonstrate the positive role that science can play within sport and contribute to protecting the health of athletes involved."

Seb Coe, Chair of the London Organising Committee of the Olympic Games and Paralympic Games, said: "Today’s announcement between GSK and WADA demonstrates that the passion and enthusiasm to deliver a clean Games for London 2012 has grown into a genuine legacy for sport and athletes. We now see a large global organization creating a new way of working through a dedicated partnership that will live on beyond London 2012."

About the Partnership

GSK has worked with WADA to establish a formal scientific review process within its Research and Development teams to help identify as early as possible drugs with potential for sports-related abuse. This includes regular reviews at key research milestones.

Efforts to formalize sensitive information sharing with WADA have been underway across the pharmaceutical industry since the IFPMA (International Federation of Pharmaceutical Manufacturers and Associations) signed a Joint Declaration with WADA in July 2010. The agreement, ‘Cooperation in the Fight against Doping in Sport’, aimed to facilitate cooperation between industry and WADA.

GlaxoSmithKline

One of the world’s leading research-based pharmaceutical and healthcare companies, GSK is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

For more information, contact:wada@wada-ama.org

As a service to our readers, Around the Rings will provide verbatim texts of selected press releases issued by Olympic-related organizations, federations, businesses and sponsors.

These press releases appear as sent to Around the Rings and are not edited for spelling, grammar or punctuation.

Your complete source of news about the Olympics is www.aroundtherings.com, for subscribers only.

Guardar

Últimas Noticias

Sinner-Alcaraz, the duel that came to succeed the three phenomenons

Beyond the final result, Roland Garros left the feeling that the Italian and the Spaniard will shape the great duel that came to help us through the duel for the end of the Federer-Nadal-Djokovic era.
Sinner-Alcaraz, the duel that came

Table tennis: Brazil’s Bruna Costa Alexandre will be Olympic and Paralympic in Paris 2024

She is the third in her sport and the seventh athlete to achieve it in the same edition; in Santiago 2023 she was the first athlete with disabilities to compete at the Pan American level and won a medal.
Table tennis: Brazil’s Bruna Costa

Rugby 7s: the best player of 2023 would only play the medal match in Paris

Argentinian Rodrigo Isgró received a five-game suspension for an indiscipline in the circuit’s decisive clash that would exclude him until the final or the bronze match; the Federation will seek to make the appeal successful.
Rugby 7s: the best player

Rhonex Kipruto, owner of the world record for the 10000 meters on the road, was suspended for six years

The Kenyan received the maximum sanction for irregularities in his biological passport and the Court considered that he was part of a system of “deliberate and sophisticated doping” to improve his performance. He will lose his record and the bronze medal at the Doha World Cup.
Rhonex Kipruto, owner of the

Katie Ledecky spoke about doping Chinese swimmers: “It’s difficult to go to Paris knowing that we’re going to compete with some of these athletes”

The American, a seven-time Olympic champion, referred to the case of the 23 positive controls before the Tokyo Games that were announced a few weeks ago and shook the swimming world. “I think our faith in some of the systems is at an all-time low,” he said.
Katie Ledecky spoke about doping